On the other hand, TP53 is associated with a poor prognosis in pancreatic cancer and increased resistance to cancer therapy (Chen et al., 2021), meanwhile, defective TP53 function accelerates cancer cell development and impairs tumor response to DNA-damaging drugs. Here, TP53 is linked to cancer.